Tin tức & Cập nhật

Add-on vildagliptin improves outcomes in patients with diabetes, CAD

28 Jan 2021

Patients with type 2 diabetes mellitus (T2DM) and symptomatic coronary artery disease (CAD) treated with metformin fare better with the addition of vildagliptin versus glimepiride, as the former is associated with better glycaemic control and lipid profile, according to a study.

Add-on vildagliptin improves outcomes in patients with diabetes, CAD

28 Jan 2021

Anti-TNF exposure may increase BMI in children with Crohn’s disease

28 Jan 2021 bởi

Exposure to anti-TNF therapy appears to be associated with an increased body mass index (BMI) z-score in paediatric patients with Crohn’s disease, according to a study presented at Crohn’s & Colitis Congress 2021.

Anti-TNF exposure may increase BMI in children with Crohn’s disease

28 Jan 2021

UNITY-CLL: Umbralisib + ublituximab prolongs PFS in CLL

28 Jan 2021 bởi

A combination therapy of umbralisib + ublituximab (U2) significantly improves progression-free survival (PFS) in patients with chronic lymphocytic leukaemia (CLL) compared with obinutuzumab + chlorambucil (O+Chl), according to the UNITY-CLL* study presented at ASH 2020.

UNITY-CLL: Umbralisib + ublituximab prolongs PFS in CLL

28 Jan 2021

Prophylactic azithromycin does not improve lung function in paediatric HIV-related lung disease

27 Jan 2021 bởi

A once-weekly prophylactic dose of azithromycin does not improve lung function in children with HIV-associated chronic lung disease (HCLD), according to results of the BREATHE* trial. However, azithromycin was associated with a reduction in acute respiratory exacerbations (AREs).

Prophylactic azithromycin does not improve lung function in paediatric HIV-related lung disease

27 Jan 2021

Omadacycline noninferior to moxifloxacin in patients with PORT risk class III, IV CABP

27 Jan 2021 bởi

In the treatment of patients with community-acquired bacterial pneumonia (CABP), omadacycline is as effective as moxifloxacin at inducing response in patients with Pneumonia Patient Outcomes Research Team (PORT) risk class III and IV, according to data from the phase III OPTIC* trial.

Omadacycline noninferior to moxifloxacin in patients with PORT risk class III, IV CABP

27 Jan 2021

Which sequence is most efficacious for PD-1/L1 inhibitors, carboplatin-based chemotherapy?

27 Jan 2021

Cisplatin-ineligible patients with metastatic urothelial carcinoma treated with PD-1/L1 inhibitor followed by carboplatin-containing chemotherapy show similar overall survival (OS) with those treated with the reverse sequence, a study has found.

Which sequence is most efficacious for PD-1/L1 inhibitors, carboplatin-based chemotherapy?

27 Jan 2021

Amiselimod exhibits favourable safety in healthy individuals

27 Jan 2021 bởi

Amiselimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, demonstrated a favourable safety profile among healthy individuals, according to a phase I study presented at Crohn’s and Colitis 2021.

Amiselimod exhibits favourable safety in healthy individuals

27 Jan 2021

Adjunctive use of vibegron feasible in BPH with persistent storage symptoms

27 Jan 2021

Use of vibegron in addition to α-1 blocker or phosphodiesterase 5 (PDE5) inhibitor is safe and effective in the treatment of patients with benign prostatic hyperplasia (BPH) and persistent storage symptoms, as shown in a study.

Adjunctive use of vibegron feasible in BPH with persistent storage symptoms

27 Jan 2021

Baricitinib-remdesivir combo may improve COVID-19 recovery time

26 Jan 2021 bởi

The combination of baricitinib and remdesivir improved recovery time and clinical status of patients with COVID-19 compared with remdesivir monotherapy, results of the ACTT*-2 study showed.

Baricitinib-remdesivir combo may improve COVID-19 recovery time

26 Jan 2021

IBD in kids: A protracted course?

26 Jan 2021 bởi

While children with inflammatory bowel disease (IBD) see their conditions improve with biologic therapy, those with ulcerative colitis (UC) tend to have residual disease activity even after clinical remission, according to two separate studies presented at the 2021 Crohn’s and Colitis Congress.

IBD in kids: A protracted course?

26 Jan 2021

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Add-on vildagliptin improves outcomes in patients with diabetes, CAD

Add-on vildagliptin improves outcomes in patients with diabetes, CAD

Anti-TNF exposure may increase BMI in children with Crohn’s disease

Anti-TNF exposure may increase BMI in children with Crohn’s disease

UNITY-CLL: Umbralisib + ublituximab prolongs PFS in CLL

UNITY-CLL: Umbralisib + ublituximab prolongs PFS in CLL

Prophylactic azithromycin does not improve lung function in paediatric HIV-related lung disease

Prophylactic azithromycin does not improve lung function in paediatric HIV-related lung disease

Omadacycline noninferior to moxifloxacin in patients with PORT risk class III, IV CABP

Omadacycline noninferior to moxifloxacin in patients with PORT risk class III, IV CABP

Which sequence is most efficacious for PD-1/L1 inhibitors, carboplatin-based chemotherapy?

Which sequence is most efficacious for PD-1/L1 inhibitors, carboplatin-based chemotherapy?

Amiselimod exhibits favourable safety in healthy individuals

Amiselimod exhibits favourable safety in healthy individuals

Adjunctive use of vibegron feasible in BPH with persistent storage symptoms

Adjunctive use of vibegron feasible in BPH with persistent storage symptoms

Baricitinib-remdesivir combo may improve COVID-19 recovery time

Baricitinib-remdesivir combo may improve COVID-19 recovery time

IBD in kids: A protracted course?

IBD in kids: A protracted course?